GeneCentric Therapeutics

GeneCentric Therapeutics is a biotechnology company based in Durham, North Carolina. The company employs 17 people and generates over $10,000 in annual revenue. GeneCentric Therapeutics specializes in developing innovative diagnostic platforms for cancer patients. Their Lung Subtype Platform (LSP™) categorizes lung cancer patients into subtypes, aiding in the selection of appropriate treatments. This platform was licensed to Laboratory Corporation of America® Holdings (LabCorp) and is now offered through their Integrated Oncology division as HistoPlusSM: Lung Cancer. Their second platform technology, the Hypoxia Signature, aims to identify patients who are likely to respond to anti-angiogenesis therapies. The company distinguishes itself through its unique partnership model. This approach allows GeneCentric Therapeutics to focus on its core competencies in scientific research and clinical studies, while collaborating with leading clinical laboratories, in-vitro diagnostic (IVD), pharmaceutical, and biotech companies to translate scientific discoveries into clinically applicable diagnostics. For more information, visit genecentric.com.